Sensyne Health’s (SENS) Buy Rating Reaffirmed at Peel Hunt

Peel Hunt reaffirmed their buy rating on shares of Sensyne Health (LON:SENS) in a report released on Wednesday, ThisIsMoney.Co.Uk reports.

Shares of LON:SENS opened at GBX 123.50 ($1.61) on Wednesday. Sensyne Health has a 1-year low of GBX 120 ($1.57) and a 1-year high of GBX 213 ($2.78). The company has a market cap of $158.79 million and a PE ratio of 6.79. The company has a current ratio of 13.29, a quick ratio of 13.22 and a debt-to-equity ratio of 1.60.

Sensyne Health Company Profile

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts.

Featured Story: Why is the price-sales ratio important?

Receive News & Ratings for Sensyne Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensyne Health and related companies with MarketBeat.com's FREE daily email newsletter.